Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

Blood

Volumn 99, Issue 10, 2002, Pages 3861-3862

  Olavarria, Eduardo ^a   Craddock, Charles ^a   Dazzi, Francesco ^a   Marin, David ^a   Marktel, Sarah ^a   Apperley, Jane F ^a   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA INTERFERON; IMATINIB; PREDNISONE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037093061     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3861     Document Type: Article

References (15)

1. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
2. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse
3. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
4. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
5. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
6. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
7. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
8. STI-571 induces mixed chimerism in patients relapsing in blastic transformation after allogeneic stem cell transplantation for chronic myeloid leukemia
9. Clinical activity of an abl-tyrosine kinase inhibitor (STI571) in a patient with cml lymphoid blast crisis relapsing after allogeneic stem cell transplantation
10. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: An EBMT retrospective analysis: The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
11. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
12. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
13. Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia
14. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
15. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia